Brain Delivery Platform And Rare Disease Portfolio Will Support Long-Term Upside Potential

Catalysts

About Denali Therapeutics

Denali Therapeutics focuses on biologic medicines engineered to cross the blood brain barrier for rare genetic and common neurodegenerative diseases.

What are the underlying business or industry changes driving this perspective?

• The first full commercial quarter of AVLAYAH, with US$3.6 million in net product revenue and early coverage for more than 50% of commercial lives, points to an expanding rare disease franchise that can increase revenue as more eligible Hunter syndrome patients start therapy.
• Management highlights a multi-program enzyme and protein replacement portfolio that reuses the same transport vehicle platform, existing development know how, and commercial infrastructure. This structure can support additional launches across lysosomal storage disorders and help improve margins over time.
• The transport vehicle technology that enabled AVLAYAH is already in clinical use and is being applied to both antibodies and oligonucleotides. Successful readouts in Alzheimer’s disease could validate a common brain delivery approach and open large patient populations that are meaningful for long term revenue and earnings.
• Growing acceptance of biomarker based development in neurodegeneration, including progranulin and NfL in FTD GRN and established markers in Hunter syndrome, may allow Denali Therapeutics to pursue faster regulatory paths that can shorten timelines and reduce development spending relative to potential future revenue streams.
• A pro forma cash position above US$1.1b and flat operating expenses year on year in the reported quarter give the company room to fund AVLAYAH commercialization and multiple late stage programs without immediate external financing. This can help stabilize earnings power as the portfolio matures.

Assumptions

How have these above catalysts been quantified?

• This narrative explores a more optimistic perspective on Denali Therapeutics compared to the consensus, based on a Fair Value that aligns with the bullish cohort of analysts.
• Denali Therapeutics currently has no revenue. The bullish analysts are forecasting revenue to reach $1.2 billion by August 2029.
• As a pre-revenue company, The bullish analysts expect Denali Therapeutics to achieve a profit margin of 4.4% in 3 years time.
• The bullish analysts expect earnings to reach $55.0 million (and earnings per share of $0.29) by about August 2029, up from -$508.0 million today. However, there is some disagreement amongst the analysts with the more bearish ones expecting earnings as low as $-678.8 million.
• In order for the above numbers to justify the price target of the more bullish analyst cohort, the company would need to trade at a PE ratio of 183.8x on those 2029 earnings, up from -7.7x today. This future PE is greater than the current PE for the US Biotechs industry at 17.6x.
• The bullish analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 7.38%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

• Denali Therapeutics relies heavily on a single early commercial product, AVLAYAH, in a rare disease with an estimated 375 currently eligible pediatric patients in the United States. If initial interest from highly engaged families fades, or a meaningful portion of the broader population does not switch from existing therapies, revenue growth from this franchise could fall short of expectations and constrain long term earnings power.
• The long term thesis depends on the transport vehicle platform extending successfully into multiple lysosomal storage disorders and common neurodegenerative diseases. Many key programs such as DNL593, DNL628, and DNL921 are still in early or mid clinical stages with data timelines out to 2027. Any disappointing biomarker or safety outcomes, or failure to secure accelerated regulatory paths, could reduce the opportunity set and pressure future revenue and earnings.
• Management describes multi billion dollar market opportunities across enzyme replacement and Alzheimer’s programs, but Denali Therapeutics faces established and emerging competitors in Hunter syndrome, Sanfilippo syndrome, and Alzheimer’s disease, including potential new therapies and gene therapies. Pricing pressure, slower uptake, or loss of share could limit AVLAYAH and future product sales and weigh on net margins.
• Although operating expenses for the reported quarter were flat year on year and the company holds more than US$1.1b in pro forma cash, Denali Therapeutics is investing heavily in commercial infrastructure, internal manufacturing, and a broad pipeline. If product revenues do not scale as expected, or large late stage trials run longer or cost more than anticipated, cash burn could remain high and delay a move to sustained profitability and positive earnings.
• The long term story assumes that biologic brain delivery and biomarker based development become more widely accepted in neurodegeneration, yet regulatory standards for biomarkers such as NfL and tau in indications like FTD GRN and Alzheimer’s disease are still evolving. If regulators require larger or longer outcomes studies rather than biomarker driven approvals, this could extend timelines, increase development spending, and defer potential revenue and margin expansion.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The assumed bullish price target for Denali Therapeutics is $42.0, which represents up to two standard deviations above the consensus price target of $34.31. This valuation is based on what can be assumed as the expectations of Denali Therapeutics's future earnings growth, profit margins and other risk factors from analysts on the bullish end of the spectrum.
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $42.0, and the most bearish reporting a price target of just $25.0.
• In order for you to agree with the more bullish analyst cohort, you'd need to believe that by 2029, revenues will be $1.2 billion, earnings will come to $55.0 million, and it would be trading on a PE ratio of 183.8x, assuming you use a discount rate of 7.4%.
• Given the current share price of $24.73, the analyst price target of $42.0 is 41.1% higher.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.